RNA Sequencing of Early-Stage Gastric Adenocarcinoma Reveals Multiple Activated Pathways and Novel Long Non-Coding RNAs in Patient Tissue Samples.

Background Gastric cancer is among the most common cancers worldwide that currently lacks effective diagnostic biomarkers and therapeutic targets. Next-generation RNA sequencing is a powerful tool that allows rapid and accurate transcriptome-wide profiling to detect differentially expressed transcripts involved in normal biological and pathological processes. Given the function of this technique, it has the potential to identify new molecular targets for the early diagnosis of disease, particularly in gastric adenocarcinoma. Methods In this study, whole-transcriptome analysis was performed with RNA sequencing on tumoral and non-tumoral tissue samples from patients with early-stage gastric cancer. Gene ontology and pathway enrichment analysis were used to determine the main function of the specific genes and pathways present in tissue samples. Results Analysis of the differentially expressed genes revealed 5 upregulated and 234 downregulated genes in gastric cancer tissues. Pathway enrichment analysis revealed significantly dysregulated signalling pathways, including those involved in gastric acid secretion, drug metabolism and transporters, molecular toxicology, O-linked glycosylation of mucins, immunotoxicity, metabolism of xenobiotics by cytochrome P450, and glycosylation. We also found novel downregulated non-coding RNAs present in gastric cancer tissues, including GATA6 antisense RNA 1, antisense to LYZ, antisense P4HB, overlapping ACER2, long intergenic non-protein coding RNA 2688 (LINC02688) and uncharacterized LOC25845 (PP7080). Conclusion The transcriptomic data found in this study illustrates the power of RNA-sequencing in discovering novel genes ‎and tumorigenic pathways involved in human carcinogenesis. The anomalies present in these genes may serve as promising tools for the development of accurate diagnostic biomarkers for the detection of early-stage gastric cancer.

[1]  S. Fattahi,et al.  LncRNAs as potential diagnostic and prognostic biomarkers in gastric cancer: A novel approach to personalized medicine , 2020, Journal of cellular physiology.

[2]  T. Han,et al.  Screening of non-invasive miRNA biomarker candidates for metastasis of gastric cancer by small RNA sequencing of plasma exosomes. , 2019, Carcinogenesis.

[3]  S. Abass,et al.  E-Cadherin Protein as a Potential Marker for Gastric Cancer and Its Association with Helicobacter Pylori- Induced Gastritis and Gastric Ulcer. , 2019 .

[4]  N. Alajez,et al.  Integrated Transcriptome and Pathway Analyses Revealed Multiple Activated Pathways in Breast Cancer , 2019, Front. Oncol..

[5]  Ailing Zhong,et al.  Molecular profiling of mucinous epithelial ovarian cancer by weighted gene co-expression network analysis. , 2019, Gene.

[6]  Yida Pan,et al.  GKN2 promotes oxidative stress-induced gastric cancer cell apoptosis via the Hsc70 pathway , 2019, Journal of experimental & clinical cancer research : CR.

[7]  X. Yao,et al.  Gastric Parietal Cell Physiology and Helicobacter pylori-Induced Disease. , 2019, Gastroenterology.

[8]  H. Chun,et al.  Proton pump inhibitor: The dual role in gastric cancer , 2019, World journal of gastroenterology.

[9]  Yuxin Tang,et al.  Next-Generation Sequencing Analysis of mRNA Profile in Cisplatin-Resistant Gastric Cancer Cell Line SGC7901 , 2019, Medical science monitor : international medical journal of experimental and clinical research.

[10]  J. Kamińska,et al.  The role and diagnostic potential of gastrokine 1 in gastric cancer , 2019, Cancer management and research.

[11]  Maurice H. T. Ling,et al.  Advancing Personalized Medicine Through the Application of Whole Exome Sequencing and Big Data Analytics , 2019, Front. Genet..

[12]  Zhengting Wang,et al.  Surgical Compliance and Outcomes in Gastric Cancer: a population-based cohort study , 2019, Journal of Cancer.

[13]  A. Samadani,et al.  CDX1/2 and KLF5 Expression and Epigenetic Modulation of Sonic Hedgehog Signaling in Gastric Adenocarcinoma , 2019, Pathology & Oncology Research.

[14]  Mohammad Galehdari,et al.  Evaluation of GKN1 and GKN2 gene expression as a biomarker of gastric cancer , 2018, Gastroenterology and hepatology from bed to bench.

[15]  William Yang,et al.  Systems biology analysis reveals new insights into invasive lung cancer , 2018, BMC Systems Biology.

[16]  C. Ormandy,et al.  Single-Cell Transcriptomics in Cancer Immunobiology: The Future of Precision Oncology , 2018, Front. Immunol..

[17]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[18]  S. Fattahi,et al.  Infection‐associated epigenetic alterations in gastric cancer: New insight in cancer therapy , 2018, Journal of cellular physiology.

[19]  N. Méndez-Sánchez,et al.  The proton pump inhibitors use and gastric cancer development: is it a real association? , 2018, AME Medical Journal.

[20]  Jyotishman Pathak,et al.  The Role of Next-Generation Sequencing in Precision Medicine: A Review of Outcomes in Oncology , 2018, Journal of personalized medicine.

[21]  Sailaja V. Elchuri,et al.  RNA-Sequencing of Primary Retinoblastoma Tumors Provides New Insights and Challenges Into Tumor Development , 2018, Front. Genet..

[22]  W. Park,et al.  Gastrokine 1 protein is a potential theragnostic target for gastric cancer , 2018, Gastric Cancer.

[23]  C. Boland,et al.  A RNA-Sequencing approach for the identification of novel long non-coding RNA biomarkers in colorectal cancer , 2018, Scientific Reports.

[24]  A. Wong,et al.  Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study , 2017, Gut.

[25]  M. Montrose,et al.  Trefoil Factor Peptides and Gastrointestinal Function. , 2017, Annual review of physiology.

[26]  Tao Huang,et al.  Analysis of cancer-related lncRNAs using gene ontology and KEGG pathways , 2017, Artif. Intell. Medicine.

[27]  Yu-Dong Cai,et al.  Analysis of Important Gene Ontology Terms and Biological Pathways Related to Pancreatic Cancer , 2016, BioMed research international.

[28]  Ping Li,et al.  Decreased LIPF expression is correlated with DGKA and predicts poor outcome of gastric cancer , 2016, Oncology reports.

[29]  Shican Yan,et al.  The influence of marital status on the stage at diagnosis, treatment, and survival of adult patients with gastric cancer: a population-based study , 2016, Oncotarget.

[30]  S. Batra,et al.  Pathobiological implications of mucin glycans in cancer: Sweet poison and novel targets. , 2015, Biochimica et biophysica acta.

[31]  Xin He,et al.  Role of Metabolic Enzymes P450 (CYP) on Activating Procarcinogen and their Polymorphisms on the Risk of Cancers. , 2015, Current drug metabolism.

[32]  Hui Sun,et al.  Identification of key genes associated with gastric cancer based on DNA microarray data , 2015, Oncology letters.

[33]  Hao Wang,et al.  Effects of gastrokine-2 expression on gastric cancer cell apoptosis by activation of extrinsic apoptotic pathways , 2014, Molecular medicine reports.

[34]  Peng-jun Zhang,et al.  Identification and characterization of novel serum microRNA candidates from deep sequencing in cervical cancer patients , 2014, Scientific Reports.

[35]  P. Tassone,et al.  Aberrant Glycosylation as Biomarker for Cancer: Focus on CD43 , 2014, BioMed research international.

[36]  Sang Min Park,et al.  Acid suppressive drugs and gastric cancer: a meta-analysis of observational studies. , 2013, World journal of gastroenterology.

[37]  M. Schwab,et al.  Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. , 2013, Pharmacology & therapeutics.

[38]  H. Chae,et al.  Expression of MUC5AC and Trefoil Peptide 1 (TFF1) in the Subtypes of Intestinal Metaplasia , 2012, Clinical endoscopy.

[39]  J. Coebergh,et al.  Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: a population-based study in the Netherlands. , 2010, European journal of cancer.

[40]  M Ingelman-Sundberg,et al.  Cytochrome P450 pharmacogenetics and cancer , 2006, Oncogene.

[41]  J. Merchant,et al.  Chronic gastritis in the hypochlorhydric gastrin-deficient mouse progresses to adenocarcinoma , 2005, Oncogene.

[42]  G. Murray,et al.  Cytochrome P450 CYP1B1 activity in renal cell carcinoma , 2004, British Journal of Cancer.

[43]  H. Yoo,et al.  Expression profiling and subtype-specific expression of stomach cancer. , 2003, Cancer research.

[44]  G. Murray,et al.  Enhanced expression of cytochrome P450 in stomach cancer. , 1998, British Journal of Cancer.

[45]  Chang-Hwei Chen,et al.  Genetic Variations and Polymorphisms of Metabolic Enzymes , 2020, Xenobiotic Metabolic Enzymes: Bioactivation and Antioxidant Defense.

[46]  Chang-Hwei Chen,et al.  Xenobiotic Metabolic Enzymes: Bioactivation and Antioxidant Defense , 2020 .